The FDA has issued two complete response letters (CRL) to Phathom Pharmaceuticals, one for a new drug application (NDA) for its acid suppressant vonoprazan for treating erosive esophagitis and another for a postapproval supplement for Voquezna, a combination therapy previously approved for treating Helicobacter pylori infections.
Source: Drug Industry Daily